HCPLive

07/23/2025

Hypertrophic cardiomyopathy (HCM) affects an estimated 660,000 Americans, but many remain undiagnosed. Women, in particular, face delayed diagnoses due to symptom overlap and gender bias in care. Dr. Stephen Heitner, VP, Head of Clinical Research at Cytokinetics, breaks down why HCM is so often missed and what healthcare providers can do to close the gap.

Learn how earlier recognition can change outcomes: bit.ly/4lSMnQX

07/23/2025

Grateful to Dr. Surya Bhatt for leading a thoughtful and dynamic discussion during our recent Clinical Forum on the role of biologics in modern asthma and COPD management.

It was a meaningful exchange among top pulmonology experts diving into the evolving landscape of biologic therapies, their impact on treatment strategies, and the latest insights from clinical trials.

Thanks to all who joined and shared their perspectives. It’s these kinds of conversations that drive real progress for patients.

Follow HCPLive® for more expert-led forums exploring what’s next in clinical care.

07/23/2025

We sat down with Marat Fudim, MD, to discuss the role GLP-1 receptor agonists play in heart failure now and in the future. He also explained the importance of the human aspect in remote patient monitoring.

Watch now: https://hubs.li/Q03ymYGT0

07/23/2025

Pneumococcal vaccination was associated with reduced hospitalizations and reduced severity of COVID-19 course and outcomes in people with inflammatory rheumatic diseases like . Read more now: https://hubs.li/Q03ymWW-0

07/23/2025

The National Institute for Health and Care Excellence now backs betula verrucosa (Itulazax) for allergic rhinitis or conjunctivitis caused by birch pollen. This treatment reduces symptoms while targeting the underlying immune response. # conjunctivitis

The National Institute for Health and Care Excellence endorses betula verrucosa for long-term relief from severe birch tree allergies, such as allergic rhinitis or conjunctivitis.

07/22/2025

NEW: Findings from a randomized, double-blind, sham-controlled crossover study conducted at McMaster University Medical Center suggest only some patients with IBS and self-perceived gluten sensitivity have symptoms triggered by gluten or wheat.

Despite learning that neither was triggering their symptoms, most patients continued a gluten-free diet.

Learn more:

Study findings showed IBS patients with self-perceived gluten sensitivity reacted similarly to gluten, wheat, and sham challenges.

07/22/2025

Big thanks to Dr. Hanford Yau for moderating an incredible Clinical Forum on emerging therapies for the management of Cushing syndrome. Leading nephrology experts came together for an engaging, evidence-driven conversation focused on patient-centered treatment strategies.

From current management strategies to the potential of new treatments, the forum explored how clinicians can navigate complex decisions and improve patient outcomes.

Thank you to everyone who attended and contributed to the discussion. Collaboration like this is how we advance care.

Stay connected with HCPLive® for more forums that spotlight clinical progress.

07/22/2025

Discover how emerging therapies like aprocitentan can help manage resistant hypertension in patients with comorbid conditions like chronic kidney disease. Accurate diagnosis and optimized treatment are key to improving outcomes.

Watch Now: https://hubs.li/Q03s1-Bw0

07/22/2025

In the newest episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss some of the most exciting news from the Endocrine Society's 2025 annual meeting.

Watch now: https://hubs.li/Q03y7yWH0

07/22/2025

Deucravacitinib is up for review to be the potential first approved TYK2 inihibtor for psoriatic treatment. Learn more: https://hubs.li/Q03ybvBG0

07/22/2025

New research suggests prior vaccination against COVID-19 may play a critical role in improving renal outcomes and overall survival in patients with and COVID-19 infection.

Learn more: https://hubs.li/Q03y7GV10

07/22/2025

Hassan Hamade, MD, of the Icahn School of Medicine at Mount Sinai, spoke about some of the most notable takeaways on deucravacitinib for psoriasis from an HCPLive Clinical Forum on plaque .

View more: https://hubs.li/Q03y7D9Z0